Reported 1 day ago
Bank of America Securities recently maintained a Buy rating for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), setting a price target of $79.00. The company reported $166 million in revenue for Q2 2025, with notable contributions from its products Crysvita® and Dojolvi®. Despite this optimism, the report suggests that certain AI stocks may offer better investment opportunities with less risk.
Source: YAHOO